ML385, a selective inhibitor of Nrf2, demonstrates efficacy in the treatment of adult T-cell leukemia. Ishikawa C, Mori N. Leuk Lymphoma 2024 Dec 17:1-12. doi: 10.1080/10428194.2024.2441875.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ishikawa C, Mori N. ML385, a selective inhibitor of Nrf2, demonstrates efficacy in the treatment of adult T-cell leukemia. Leuk Lymphoma 2024 Dec 17:1-12. doi: 10.1080/10428194.2024.2441875.
PMID: 39689304